Solid Biosciences Inc. (SLDB) intrinsic value & 10-year financials
Solid Biosciences Inc. (SLDB) has a Graham intrinsic value of $124.71 per share. At $5.53 on Oct 17, 2026, the stock trades 96% below that value.
- Graham intrinsic value
- $124.71
- Share price (Oct 17, 2026)
- $5.53
- Price vs Graham value
- 96% below
- Market cap
- $483.9M
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- -40.6%
- ROIC (10-yr avg)
- 25.0%
- Free cash flow (FY2025)
- -$157.4M
SLDB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$174.3M | -$1.99 | -$157.4M | — | -164.9% |
| FY2024 | — | -$124.7M | -$3.06 | -$100.7M | — | -167.8% |
| FY2023 | — | -$96.0M | -$2.42 | -$95.7M | — | -131.4% |
| FY2022 | $8.1M | -$86.0M | -$5.05 | -$101.0M | -1315.2% | -123.8% |
| FY2021 | $13.6M | -$72.2M | -$5.07 | -$79.0M | -530.5% | -206.6% |
| FY2020 | $0 | -$88.3M | -$6.38 | -$57.5M | — | 1674.0% |
| FY2019 | $0 | -$117.2M | — | -$97.1M | — | -488.7% |
| FY2018 | $0 | -$74.8M | — | -$78.0M | — | -190.8% |
| FY2017 | $0 | -$52.1M | — | -$45.5M | — | — |
| FY2016 | $0 | -$21.5M | — | -$20.5M | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Solid Biosciences Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Solid Biosciences Inc. has historically struggled to out-earn its cost of capital, averaging just -31.3% ROIC.
Solid Biosciences Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Solid Biosciences Inc. is modeled at -40.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $124.71 per share.